Offer Request Form

Order list is empty

Shikari® (Q-PAL) Palivizumab ELISA

Enzyme immunoassay for the quantitative determination of Palivizumab (Synagis®) in serum and plasma.

This kit has been especially developed for the quantitative determination of infliximab in serum and plasma samples between the Cmin and Cmax range of concentrations.

Palivizumab Drug Bank Accession Number is DB00110.

Palivizumab is a monoclonal anti respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients. Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

All SHIKARI® ELISA kits are suitable for biosimilar work. 

All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.

For technical inquiry, please contact

Required Volume (µl) 10
Total Time (min) 70
Sample Serum, plasma
Sample Number 96
Detection Limit (ng/mL) 3
Spike Recovery (%) Between 85-115
Shelf Life (year) 1
Assay type Quantitative
Species Reactivity Human
Storage conditions Store at +4°C. Please refer to protocols.
Shipping conditions At room temperature
# File Action
Instructions For Use Download
Safety Data Sheet (SDS) Download
Validation Report Download

Publications with this drug

# File Action